Salvatore Caruso
No ORCID on file
· 16 papers in corpus
· active 2011-2025
Study types
- article 9
- letter 1
- other 1
- preprint 1
- rct 1
Condition tags
- endometriosis 11
- chronic_pelvic_pain 9
- dyspareunia 5
- dysmenorrhea 4
Top journals
Frequent coauthors
- Antonio Cianci 11
- Stefano Cianci 11
- Caruso S 9
- Cianci A 7
- Iraci Sareri M 7
- Valentina Fava 6
- Marco Iraci 5
- Caruso G 5
- Marco Iraci Sareri 5
- Giuseppe Caruso 4
letter
2025
article
2024
OBJECTIVE: To compare the effects of five combined oral contraceptives (COCs) - ethinylestradiol (EE) 30 μg/dienogest (DNG) 2 mg, EE 20 μg/drospirenone (DRSP) 3 mg, 17β-estradiol (E2) 1.5 mg/nomegestrol acetate (NomAc) 2.5 mg,estetrol (E4) …
2022
Among the components of a healthy life, sexuality is essential, contributing to both the psychophysical and social well-being of women and, consequently, to their quality of life. A poorly investigated standpoint is the acceptability of con…
rct
2022
BACKGROUND: To evaluate the effects of a combined oral contraceptive containing 1.5 mg 17b-estradiol (E2) and 2.5 mg nomegestrol acetate (NOMAC) or 2 mg/daily dienogest (DNG) oral progestin on endometriosis-associated chronic pelvic pain (C…
preprint
2022
Abstract Background: To evaluate the effects of a combined oral contraceptive containing 1.5mg 17b-estradiol (E2) and 2.5mg nomegestrol acetate (NOMAC) or 2 mg/daily dienogest (DNG) oral progestin on endometriosis-associated chronic pelvic …
article
2021
article
2021
Intrauterine pathologies are common in postmenopausal women and clinicians must identify signs and symptoms accurately to provide the adequate diagnosis and treatment. The quality of life (QoL) and sexuality of women are important outcomes …
other
2020
Background: To evaluate the effects of a 24/4 regimen combined oral contraceptive (COC) containing 1.5 mg 17β-estradiol (E2) and 2.5 mg nomegestrol acetate (NOMAC) compared to on-demand nonsteroidal anti-inflammatory drugs (NSAIDs) on women…
article
2019
Salvatore Caruso,1,2 Marco Iraci,1 Stefano Cianci,1 Salvatore Giovanni Vitale,1 Valentina Fava,1,2 Antonio Cianci1,21Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy; 2Research Group for …
article
2019
Purpose: The aim of this prospective study was to evaluate quality of life (QoL) and sexual function of women affected by endometriosis pain treated with Dienogest (DNG) for 24 months. Patients and methods: Fifty-four women constituted the …
review
2018
The Human Genome Project led to the discovery that about 80% of our DNA is transcribed in RNA molecules. Only 2% of the human genome is translated into proteins, the rest mostly produces molecules called non-coding RNAs, which are a heterog…
article
2016
PurposeTo evaluate the effects of a continuous regimen combined oral contraceptive (COC) containing 2 mg dienogest and 30 µg ethinyl estradiol (DNG/EE) compared to a 21/7 regimen on the quality of life (QoL) and sexual function in women aff…
article
2015
AIM: The aim of this paper was to evaluate the effects of the association between palmitoylethanolamide (PEA) and α-lipoic acid (LA) on quality of life (QoL) and sexual function in women affected by endometriosis-associated pelvic pain. MET…
article
2015
PurposeThe aim of the study was to evaluate the effects of dienogest (DNG) on quality of life (QoL) and sexual function of women affected by endometriosis pain.MethodsFifty-four women constituted the study group and were given 2 mg/daily DN…
2014
Introductionfallopian tube choriocarcinoma coexistent with viable intrauterine pregnancy is an extremely rare condition.Case reportwe present the first case reported in literature of tubal choriocarcinoma coexistent with viable intrauterine…
article
2011
INTRODUCTION: A new oral contraceptive containing the natural estrogen estradiol and a 19-nortestosterone derivate dienogest (DNG) in a four-phasic 28-day regimen may be used by women. AIM: To investigate the quality of sexual life of healt…